DNA

IBS Capital sells IQuum stake to Roche

Tue, 17/06/2014 - 11:41

IBS Capital has sold its equity investment in IQuum to Roche. 

IBS made its initial capital investment in IQuum in 1999 shortly after the firm was founded and has remained its largest outside investor over the past 15 years. 
 
David Taft, the president of IBS, also served as a director on IQuum's board of directors since 1999.  During this period, IQuum developed groundbreaking technology in molecular diagnostics. 
 
Taft says: "IQuum's Laboratory-in-a-tube (Liat) System will dramatically improve the point of care segment of the diagnostics market and will bring significant benefits to Roche.  In combination with Roche's extensive technological, marketing and financial resources, the Liat system will provide healthcare clinics and hospitals with fast, accurate and simple to use testing for a wide range of medical conditions."


Subscribe to free daily newsletter
morenews

Cayman Islands funds

Fri, 19/Dec/2014 - 11:23

Championing the emerging manager

Fri, 19/Dec/2014 - 11:02

Cayman fund managers prepare for FATCA

Fri, 19/Dec/2014 - 10:57

latestjobs
Java/Scala Developer

Fri, 19 Dec 2014 00:00:00 GMT

Senior Java Software Developer – Fin Tech – SF

Fri, 19 Dec 2014 00:00:00 GMT

Senior/Lead Software Development Openings

Fri, 19 Dec 2014 00:00:00 GMT

events
3 weeks 3 days from now - New Orleans
4 weeks 5 days from now - Boston
4 weeks 5 days from now - New York
5 weeks 2 days from now - New York
specialreports